Background Long-acting bronchodilators are first-line treatment for chronic obstructive
pulmonary disease (COPD), and their efficacy on lung function and clinical parameters is …

Purpose Inappropriate use of an inhaled corticosteroid (ICS) for COPD has clinical and
economic disadvantages. This retrospective analysis of The UK Health Improvement …

Introduction Limited prospective evidence is available to guide selection of first-line
maintenance therapy in patients with COPD. This pre-specified analysis of the EMAX trial …

Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death
worldwide. 1 Exacerbations of the disease, that call for additional therapeutic measures, are …

abstract Incidence, predictors and effect of discontinuation of long-acting bronchodilators on
the risk of death or hospital admission among adults with Chronic Obstructive Pulmonary …

Abstract Long-acting β 2-agonist (LABA)/long-acting muscarinic-antagonist (LAMA) dual
therapy has been found to be more effective than LAMA monotherapy in the treatment of …

Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …

Introduction Accumulated high-quality data from randomised controlled trials (RCTs)
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …

Objectives This study aimed to identify and investigate changes in the mortality of patients
with chronic obstructive pulmonary disease (COPD) at the same institute from the 1990s to …